Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV

Phase 2

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Invasive Meningococcal Disease

Drug Information

Target Indication

Invasive Meningococcal Disease

Clinical Trial

Last updated: 10/16/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Related Pipeline

Hypertension

Pathological Myopia

Renal Interstitial Fibrosis

Hypertension

Prostatic Neoplasms

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts